Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Exelixis, Inc. - Common Stock
(NQ:
EXEL
)
44.36
-0.01 (-0.02%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Investors should take notice of NASDAQ:EXEL—it offers a great deal for the fundamentals it presents.
↗
December 20, 2024
EXELIXIS INC (NASDAQ:EXEL) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via
Chartmill
Peering Into Exelixis's Recent Short Interest
↗
December 18, 2024
Via
Benzinga
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts
↗
December 17, 2024
Via
Benzinga
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
↗
December 17, 2024
Via
Benzinga
NASDAQ:EXEL is showing decent growth, but is still valued reasonably.
↗
December 16, 2024
EXELIXIS INC (NASDAQ:EXEL) is showing good growth, while it is not too expensive.
Via
Chartmill
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
↗
December 13, 2024
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends.
Via
Benzinga
Earnings Preview: Exelixis
↗
October 28, 2024
Via
Benzinga
1 No-Brainer Stock to Buy With $40
↗
October 23, 2024
The midcap biotech just became an even better buy.
Via
The Motley Fool
Analyst Ratings For Exelixis
↗
October 21, 2024
Via
Benzinga
2 Biotech Stocks to Buy Hand Over Fist in December
↗
December 07, 2024
Via
The Motley Fool
End Of Year Rally: 3 Stocks To Watch (InterDigital, Futu Holdings, Exelixis)
↗
December 01, 2024
As the calendar winds down, the stock market often heats up. This
Via
Talk Markets
Topics
Stocks / Equities
Ten Young Ones
↗
November 30, 2024
Here are a variety of lesser-known charts from my “Recents” watch list. Quite a few of them look like good bullish plays.
Via
Talk Markets
Topics
Stocks / Equities
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
↗
November 29, 2024
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.
Via
Chartmill
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
November 27, 2024
From
Exelixis, Inc.
Via
Business Wire
Navigating 16 Analyst Ratings For Exelixis
↗
October 21, 2024
Via
Benzinga
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
November 26, 2024
From
Exelixis, Inc.
Via
Business Wire
BioNTech Stock Got A IBD RS Rating Lift
↗
November 14, 2024
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance.
Via
Investor's Business Daily
Vericel Stock Sees RS Rating Shoot Higher
↗
November 11, 2024
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.
Via
Investor's Business Daily
NASDAQ:EXEL is an undervalued gem with solid fundamentals.
↗
November 08, 2024
For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.
Via
Chartmill
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
November 07, 2024
From
Exelixis, Inc.
Via
Business Wire
3 Magnificent Stocks Under $100 to Buy in November
↗
November 03, 2024
The price could be right for these stocks.
Via
The Motley Fool
Reddit, Roblox And Garmin Are Among Top 10 Large Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
↗
November 03, 2024
The top 10 performers last week were Reddit, Paycom, Mobileye, Exelixis, Garmin, Roblox, Twilio, Snap, Waters, and Atlassian. Many analysts raised price forecasts.
Via
Benzinga
Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday
↗
October 30, 2024
Via
Benzinga
Exelixis (EXEL) Q3 2024 Earnings Call Transcript
↗
October 30, 2024
EXEL earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
October 29, 2024
From
Exelixis, Inc.
Via
Business Wire
Biotech Momentum Trades For The Q4 Rally
↗
October 29, 2024
The biotech sector made an interim peak in late February followed by an active summer in very choppy trading.
Via
Talk Markets
Momentum Has Narrowed Again, Significantly
↗
October 28, 2024
It is more of a stock pickers market than usual as momentum factors are currently exaggerated.
Via
Talk Markets
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
↗
October 18, 2024
In a market where value is scarce, EXELIXIS INC (NASDAQ:EXEL) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
October 15, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
October 15, 2024
From
Exelixis, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today